PDS Biotechnology (STU:EU6) LT-Debt-to-Total-Asset : 0.20 (As of Dec. 2024)

View and export this data going back to 2016. Start your Free Trial

What is PDS Biotechnology LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. PDS Biotechnology's long-term debt to total assests ratio for the quarter that ended in Dec. 2024 was 0.20.

PDS Biotechnology's long-term debt to total assets ratio declined from Dec. 2023 (0.33) to Dec. 2024 (0.20). It may suggest that PDS Biotechnology is progressively becoming less dependent on debt to grow their business.

PDS Biotechnology LT-Debt-to-Total-Asset Historical Data

The historical data trend for PDS Biotechnology's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PDS Biotechnology LT-Debt-to-Total-Asset Chart

PDS Biotechnology Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.02

0.30

0.33

0.20

PDS Biotechnology Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.33	0.24	0.23	0.23	0.20

PDS Biotechnology LT-Debt-to-Total-Asset Calculation

PDS Biotechnology's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2024 is calculated as

LT Debt to Total Assets (A: Dec. 2024 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2024 )	/	Total Assets (A: Dec. 2024 )
	=	8.85	/	43.318
	=

PDS Biotechnology's Long-Term Debt to Total Asset Ratio for the quarter that ended in Dec. 2024 is calculated as

LT Debt to Total Assets (Q: Dec. 2024 )	=	Long-Term Debt & Capital Lease Obligation (Q: Dec. 2024 )	/	Total Assets (Q: Dec. 2024 )
	=	8.85	/	43.318
	=

PDS Biotechnology (STU:EU6) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

PDS Biotechnology LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of PDS Biotechnology's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

PDS Biotechnology Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » PDS Biotechnology Corp (STU:EU6) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

PDSB:USA EU6:Germany

Address

303A College Road, East Princeton, NJ, USA, 08540

Website

https://www.pdsbiotech.com

PDS Biotechnology Corp operates as a clinical stage biotechnology company, principally involved in drug discovery in the United States. It is engaged in the treatment of various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products are based on the proprietary Versamune platform technology, which activates and directs the human immune system to unleash a powerful and targeted attack against cancer cells.

PDS Biotechnology Headlines

No Headlines